ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

ODAC Votes 10-0 In Favor Of Avastin For Recurrent Glioblastoma Multiforme

April 3, 2009

“Whatever Happened To…?” ACS Follows Up Five Years Later

August 26, 1977

In Brief: Cancer An Alteration In Gene Expression, Not Change In Structure, Tulane Biologist Reports

March 27, 1981

What Is and Isn’t a Crime in Texas: CPRIT Official Indicted For Skipping Peer Review

December 13, 2013

Physician Clinical Investigator Awards

April 15, 1983

Olaparib, A PARP Inhibitor, Can Reduce Tumor Size In Advanced Ovarian Cancer

August 27, 2010